ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in ...
Danish pharmaceutical giant Novo Nordisk was hit with a class action lawsuit in New York federal court on Friday for allegedly misusing its patents to maintain a monopoly on its diabetes drug Victoza.
Smith Drug asked the court for an unspecified amount of monetary damages on behalf of a proposed class of Victoza purchasers ...
In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...
Novo Nordisk faces a class action lawsuit for allegedly monopolizing its diabetes drug Victoza through patent misuse and ...
Teva Pharmaceutical Industries (TEVA) is back on investor radars after recent share price swings, with the stock closing at ...
Novo Nordisk (NVO) faces a class action suit over claims it ran a pay-for-delay deal with Teva (TEVA) to delay generics for its diabetes drug Victoza. Read more here.
By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...
Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results